Euroscreen S.A.

Euroscreen's research activities began with the science of deorphanizing G-Protein-Coupled-Receptors (GPCRs).  This has been an important source of new targets for the development of our drug discovery programs and the patent portfolio.

While this is a very competitive area, Euroscreen has one of the best, scientific track records of any biopharmaceutical company today for deorphanizing GPCRs, having now accomplished such success stories 13 times in our history.

The Company's R&D combines our reagents, equipment and technologies to drive the deorphanization research.  One of our competitive advantages comes from the wide collection of human and animal tissue extracts used for the screening and identification of natural ligands for orphan GPCRs.  These extracts are processed using various protocols to obtain either peptides, proteins, biogenic amines or lipid candidates as sources of GPCR ligands.  Moreover, most of the orphan human GPCRs have been cloned and expressed in recombinant cell lines adapted to functional screening.

This expertise has been recognized by pharmaceutical companies that entered into collaborative programs with Euroscreen for selected orphan GPCRs, like Solvay Pharmaceuticals and Novartis.